Imvelaphi

I-Canagliflozin yinoveli, inamandla, kwaye ikhetha kakhulu i-sodium glucose co-transporter (SGLT) 2 inhibitor [1]. Kufunyaniswe ukuba iCanagliflozin inokonyusa ukukhutshelwa kweglucose yomchamo ngokunciphisa umyinge weswekile ezintso kunye nokunciphisa ukufunxwa kwakhona kweglucose ehluziweyo [2].

I-Canagliflozin iboniswe ukuba inqanda ukungena kwe-Na+-mediated 14C-AMG kwi-CHO-hSGLT2, i-CHO-rat SGLT2 kunye ne-CHO-mouse SGLT2 kunye ne-IC50 ixabiso le-4.4, 3.7 kunye ne-2.0 nM, ngokulandelanayo [1].

I-Canagliflozin iye yaxelwa ukuba yehlise i-glucose yegazi (BG) amanqanaba edosi-ngokuxhomekeka kuzo zombini i-db/db Iimpuku kunye ne-Zucker diabetesic fatty (ZDF) Rats. Ukongeza, i-canagliflozin ibonakalise ukuwehlisa umlinganiselo wokuphefumla, kunye nobunzima bomzimba kwiimpuku ze-DIO kunye neempuku ze-ZDF [1].

I-Canagliflozin inokuthatyathwa ngomlomo [1].

IiReferensi:
[1] Liang Y1, Arakawa K, Ueta K, Matsushita Y, Kuriyama C Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K. Impembelelo ye-canagliflozin kwi-renal threshold kwi-glucose, i-glycemia, kunye nobunzima bomzimba kwiimodeli zezilwanyana eziqhelekileyo kunye nesifo seswekile. I-PLoS enye. 2012;7(2):e30555
[2] USarnoski-Brocavich S, uHilas O. Canagliflozin (Invokana), i-Agent yomlomo yeNoveli ye-Type-2 Diabetes. P T. 2013 Nov;38(11):656-66

Imveliso Citation

Bahia Abbas Moussa, Marianne Alphonse Mahrouse, et al. "Iindlela ezahlukeneyo zokuxazulula iindlela zokulawula i-spectra edibeneyo: Isicelo sokumisela i-novel co-formulated iziyobisi ze-hypoglycemic kwifomu yabo yedosi edibeneyo yonyango." I-Spectrochimica Acta Icandelo A: I-Molecular and Biomolecular Spectroscopy Ifumaneka kwi-intanethi ye-20 Juni 2018.

Ubume beMichiza